24/7 Market News Snapshot 29 October, 2024 – GlycoMimetics, Inc. (NASDAQ:GLYC)

October 29, 2024

DENVER, Colo., 29 October, 2024 (247marketnews.com) – (NASDAQ:GLYC) are discussed in this article.
GlycoMimetics, Inc. (NASDAQ:GLYC) has captured market attention with a notable pre-market surge, climbing 179.43% to reach $0.470 from a prior close of $0.168. The substantial increase is reflective of heightened investor enthusiasm, bolstered by an impressive trading volume of 7.31 million shares. This activity indicates a robust market sentiment surrounding the company, sparking speculation about potential further gains.

This surge coincides with the recent announcement by GlycoMimetics detailing the outcome of a Phase 2 analysis from its adaptive Phase 2/3 study of uproleselan, in collaboration with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology. The study assessed the efficacy of uproleselan in conjunction with the established chemotherapy regimen known as 7+3, specifically targeting adults aged 60 and older diagnosed with acute myeloid leukemia (AML). Although the results did not yield a statistically significant improvement in event-free survival (EFS) compared to standard chemotherapy, GlycoMimetics is working closely with the Alliance to analyze the collected data, including subgroup assessments, to explore potential efficacy signals amongst certain patient demographics.

The upcoming medical conference will feature these findings from the NCI, allowing for a deeper understanding of their implications. Despite the challenges faced, GlycoMimetics remains dedicated to its objectives of innovating transformative therapies that address substantial unmet medical needs within oncology. With a distinctive chemistry platform centered on glycobiology, the company is committed to the development of novel small molecule drugs—known as glycomimetics—to combat various disease states including cancer and inflammatory conditions. As the organization progresses, further updates and developments will be communicated to stakeholders and the public.

Related news for (GLYC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.